Tags

Type your tag names separated by a space and hit enter

Revisiting global cognitive and functional state 13 years after a clinical trial of lithium for mild cognitive impairment.
Braz J Psychiatry. 2023 Mar 11; 45(1):46-49.BJ

Abstract

OBJECTIVES

To re-evaluate a sample of older adults enrolled in a randomized controlled trial of lithium for amnestic mild cognitive impairment (MCI) after 11 to 15 years, re-assessing their current (or last available) global cognitive and functional state.

METHODS

We recalled all former participants of the Lithium-MCI trial conducted by our group between 2009 and 2012 to perform a single-blinded, cross-sectional evaluation of their global clinical state to compare the long-term outcome of those who received lithium vs. those who received placebo.

RESULTS

Of the original sample (n=61), we were able to reach 36 participants (59% of retention), of whom 22 had previously received lithium (61% of the recall sample) and 14 (39%) had received placebo. Since 30.5% of the recalled sample was deceased, psychometric data were collected only for 69.5% of the participants. We found statistically significant differences in current mean Mini Mental State Examination score according to previous treatment group (25.5 [SD, 5.3] vs. 18.3 [SD, 10.9], p = 0.04). The lithium group also had better performance in the phonemic Verbal Fluency Test than the control group (34.4 [SD, 14.4] vs. 11.6 [SD, 10.10], p < 0.001). Differences in these measures also had large effect sizes, as shown by Cohen's d values of 0.92 and 1.78, respectively.

CONCLUSION

This data set suggests that older adults with amnestic MCI who had been treated with lithium during a previous randomized controlled trial had a better long-term global cognitive outcome than those from a matched sample who did not receive the intervention.

Links

Authors+Show Affiliations

Laboratório de Neurociências (LIM-27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, Brazil.

Laboratório de Neurociências (LIM-27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, Brazil.

Laboratório de Neurociências (LIM-27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, Brazil.

Laboratório de Neurociências (LIM-27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, Brazil.

Laboratório de Neurociências (LIM-27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, Brazil.

Laboratório de Neurociências (LIM-27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, Brazil.

Laboratório de Neurociências (LIM-27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, Brazil.

Laboratório de Neurociências (LIM-27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, Brazil.

Laboratório de Neurociências (LIM-27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, Brazil.

Laboratório de Neurociências (LIM-27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, Brazil.

MeSH

HumansAgedLithiumCross-Sectional StudiesCognitive DysfunctionCognitionAlzheimer Disease

Pub Type(s)

Randomized Controlled Trial

Journal Article

Language

eng

PubMed ID

36049127

Citation

Damiano, Rodolfo Furlan, et al. "Revisiting Global Cognitive and Functional State 13 Years After a Clinical Trial of Lithium for Mild Cognitive Impairment." Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999), vol. 45, no. 1, 2023, pp. 46-49.

Damiano RF, Loureiro JC, Pais MV, et al. Revisiting global cognitive and functional state 13 years after a clinical trial of lithium for mild cognitive impairment. Braz J Psychiatry. 2023;45(1):46-49.

Damiano, R. F., Loureiro, J. C., Pais, M. V., Pereira, R. F., Corradi, M. M., Di Santi, T., Bezerra, G. A. M., Radanovic, M., Talib, L. L., & Forlenza, O. V. (2023). Revisiting global cognitive and functional state 13 years after a clinical trial of lithium for mild cognitive impairment. Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999), 45(1), 46-49. https://doi.org/10.47626/1516-4446-2022-2767

Damiano RF, et al. Revisiting Global Cognitive and Functional State 13 Years After a Clinical Trial of Lithium for Mild Cognitive Impairment. Braz J Psychiatry. 2023 Mar 11;45(1):46-49. PubMed PMID: 36049127.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Revisiting global cognitive and functional state 13 years after a clinical trial of lithium for mild cognitive impairment. AU - Damiano,Rodolfo Furlan, AU - Loureiro,Julia Cunha, AU - Pais,Marcos Vasconcelos, AU - Pereira,Rodrigo Furtado, AU - Corradi,Marina de Menezes, AU - Di Santi,Talita, AU - Bezerra,Gustavo Antonio Marcolongo, AU - Radanovic,Márcia, AU - Talib,Leda Leme, AU - Forlenza,Orestes Vicente, Y1 - 2023/03/11/ PY - 2022/7/5/received PY - 2022/8/26/accepted PY - 2022/9/2/pubmed PY - 2023/3/15/medline PY - 2022/9/1/entrez KW - Alzheimer's disease KW - clinical trial KW - lithium KW - mild cognitive impairment KW - treatment SP - 46 EP - 49 JF - Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) JO - Braz J Psychiatry VL - 45 IS - 1 N2 - OBJECTIVES: To re-evaluate a sample of older adults enrolled in a randomized controlled trial of lithium for amnestic mild cognitive impairment (MCI) after 11 to 15 years, re-assessing their current (or last available) global cognitive and functional state. METHODS: We recalled all former participants of the Lithium-MCI trial conducted by our group between 2009 and 2012 to perform a single-blinded, cross-sectional evaluation of their global clinical state to compare the long-term outcome of those who received lithium vs. those who received placebo. RESULTS: Of the original sample (n=61), we were able to reach 36 participants (59% of retention), of whom 22 had previously received lithium (61% of the recall sample) and 14 (39%) had received placebo. Since 30.5% of the recalled sample was deceased, psychometric data were collected only for 69.5% of the participants. We found statistically significant differences in current mean Mini Mental State Examination score according to previous treatment group (25.5 [SD, 5.3] vs. 18.3 [SD, 10.9], p = 0.04). The lithium group also had better performance in the phonemic Verbal Fluency Test than the control group (34.4 [SD, 14.4] vs. 11.6 [SD, 10.10], p < 0.001). Differences in these measures also had large effect sizes, as shown by Cohen's d values of 0.92 and 1.78, respectively. CONCLUSION: This data set suggests that older adults with amnestic MCI who had been treated with lithium during a previous randomized controlled trial had a better long-term global cognitive outcome than those from a matched sample who did not receive the intervention. SN - 1809-452X UR - https://www.unboundmedicine.com/medline/citation/36049127/full_citation DB - PRIME DP - Unbound Medicine ER -